Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

BibTeX

@article{allodium:10.1016/j.lungcan.2025.108799,
  title = {Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 \%, and poor performance status: Transformer-based AI to characterize prognostic complexity},
  author = {Alessio Cortellini and Edoardo Garbo and Giulia La Cava and Fabrizio Citarella and Valentina Santo and Leonardo Brunetti and David J Pinato and Jarushka Naidoo and Monica Loza and Carlo Genova and Scott Gettinger and So Yeon Kim and Ritujith Jayakrishnan and Talal El Zarif and Marco Russano and Federica Pecci and Alessandro Di Federico and Michele Montrone and Dwight H Owen and Diego Signorelli and Mingjia Li and Andrea Camerini and Balazs Halmos and Bruno Vincenzi and Giulio Metro and Sai Yendamuri and Francesco Grossi and Eleni Josephides and Bartłomiej Tomasik and Raffaele Giusti and Emilio Bria and Martin Sebastian and Maximilian Rost and Fabian Acker and Lorenza Landi and Francesca Mazzoni and Alessandro Morabito and Alessandro Leonetti and Luca Cantini and Giannis Mountzios and Sukumar Kalvapudi and David O’Reilly and Eleni Karapanagiotou and Isabelle Monnet and Javier Baena and Marianna Macerelli and Margarita Majem and Aida Piedra and Diego L Cortinovis and Giuseppe Tonini and Gabriele Minuti and Laura Mezquita and Teresa Gorria and Teresa Beninato and Giuseppe Lo Russo and Arsela PrelaJ and Andrea De Giglio and Federica Biello and Frank Aboubakar Nana and Anne-Marie C. Dingemans and Joachim GJV Aerts and Roberto Ferrara and Taher Abu Hejleh and Kazuki Takada and Abdul R Naqash and Marina C Garassino and Heather A. Wakelee and Amin Nassar and Biagio Ricciuti and Paolo Soda and Camillo Maria Caruso and Valerio Guarrasi},
  year = {2025},
  journal = {Lung Cancer},
  doi = {10.1016/j.lungcan.2025.108799},
  url = {https://doi.org/10.1016/j.lungcan.2025.108799}
}

RIS

TY  - JOUR
TI  - Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity
AU  - Alessio Cortellini
AU  - Edoardo Garbo
AU  - Giulia La Cava
AU  - Fabrizio Citarella
AU  - Valentina Santo
AU  - Leonardo Brunetti
AU  - David J Pinato
AU  - Jarushka Naidoo
AU  - Monica Loza
AU  - Carlo Genova
AU  - Scott Gettinger
AU  - So Yeon Kim
AU  - Ritujith Jayakrishnan
AU  - Talal El Zarif
AU  - Marco Russano
AU  - Federica Pecci
AU  - Alessandro Di Federico
AU  - Michele Montrone
AU  - Dwight H Owen
AU  - Diego Signorelli
AU  - Mingjia Li
AU  - Andrea Camerini
AU  - Balazs Halmos
AU  - Bruno Vincenzi
AU  - Giulio Metro
AU  - Sai Yendamuri
AU  - Francesco Grossi
AU  - Eleni Josephides
AU  - Bartłomiej Tomasik
AU  - Raffaele Giusti
AU  - Emilio Bria
AU  - Martin Sebastian
AU  - Maximilian Rost
AU  - Fabian Acker
AU  - Lorenza Landi
AU  - Francesca Mazzoni
AU  - Alessandro Morabito
AU  - Alessandro Leonetti
AU  - Luca Cantini
AU  - Giannis Mountzios
AU  - Sukumar Kalvapudi
AU  - David O’Reilly
AU  - Eleni Karapanagiotou
AU  - Isabelle Monnet
AU  - Javier Baena
AU  - Marianna Macerelli
AU  - Margarita Majem
AU  - Aida Piedra
AU  - Diego L Cortinovis
AU  - Giuseppe Tonini
AU  - Gabriele Minuti
AU  - Laura Mezquita
AU  - Teresa Gorria
AU  - Teresa Beninato
AU  - Giuseppe Lo Russo
AU  - Arsela PrelaJ
AU  - Andrea De Giglio
AU  - Federica Biello
AU  - Frank Aboubakar Nana
AU  - Anne-Marie C. Dingemans
AU  - Joachim GJV Aerts
AU  - Roberto Ferrara
AU  - Taher Abu Hejleh
AU  - Kazuki Takada
AU  - Abdul R Naqash
AU  - Marina C Garassino
AU  - Heather A. Wakelee
AU  - Amin Nassar
AU  - Biagio Ricciuti
AU  - Paolo Soda
AU  - Camillo Maria Caruso
AU  - Valerio Guarrasi
PY  - 2025
JO  - Lung Cancer
DO  - 10.1016/j.lungcan.2025.108799
UR  - https://doi.org/10.1016/j.lungcan.2025.108799
ER  - 

APA

Cortellini, A., Garbo, E., Cava, G. L., Citarella, F., Santo, V., Brunetti, L., Pinato, D. J., Naidoo, J., Loza, M., Genova, C., Gettinger, S., Kim, S. Y., Jayakrishnan, R., Zarif, T. E., Russano, M., Pecci, F., Federico, A. D., Montrone, M., Owen, D. H., Signorelli, D., Li, M., Camerini, A., Halmos, B., Vincenzi, B., Metro, G., Yendamuri, S., Grossi, F., Josephides, E., Tomasik, B., Giusti, R., Bria, E., Sebastian, M., Rost, M., Acker, F., Landi, L., Mazzoni, F., Morabito, A., Leonetti, A., Cantini, L., Mountzios, G., Kalvapudi, S., O’Reilly, D., Karapanagiotou, E., Monnet, I., Baena, J., Macerelli, M., Majem, M., Piedra, A., Cortinovis, D. L., Tonini, G., Minuti, G., Mezquita, L., Gorria, T., Beninato, T., Russo, G. L., PrelaJ, A., Giglio, A. D., Biello, F., Nana, F. A., Dingemans, A. C., Aerts, J. G., Ferrara, R., Hejleh, T. A., Takada, K., Naqash, A. R., Garassino, M. C., Wakelee, H. A., Nassar, A., Ricciuti, B., Soda, P., Caruso, C. M., & Guarrasi, V. (2025). Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity. Lung Cancer. https://doi.org/10.1016/j.lungcan.2025.108799